
Michele Fornaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7011621/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a largeâ€scale metaâ€analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry, 2017, 16, 163-180.	4.8	1,082
2	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management, 2017, Volume 13, 757-777.	0.9	286
3	Understanding the Complex of Suicide in Depression: from Research to Clinics. Psychiatry Investigation, 2020, 17, 207-221.	0.7	186
4	Safety of 80 antidepressants, antipsychotics, antiâ€attentionâ€deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic metaâ€review of 78 adverse effects. World Psychiatry, 2020, 19, 214-232.	4.8	167
5	Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 20-27.	2.5	144
6	Association of Antidepressant Use With Adverse Health Outcomes. JAMA Psychiatry, 2019, 76, 1241.	6.0	143
7	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. International Journal of Molecular Sciences, 2018, 19, 2888.	1.8	137
8	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety, 2018, 9, 237-256.	1.0	130
9	The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis. Journal of Affective Disorders, 2016, 197, 259-267.	2.0	120
10	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. Frontiers in Psychiatry, 2017, 8, 148.	1.3	118
11	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. Frontiers in Psychiatry, 2016, 7, 138.	1.3	115
12	An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 2016, 15, 1329-1347.	1.0	112
13	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4â€^717â€^839 people. Lancet Psychiatry,the, 2020, 7, 52-63.	3.7	109
14	Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine, 2021, 51, 1054-1056.	2.7	104
15	A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation. Current Neuropharmacology, 2010, 8, 287-304.	1.4	103
16	Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. Lancet Psychiatry,the, 2020, 7, 955-970.	3.7	103
17	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Translational Psychiatry, 2020, 10, 152.	2.4	102
18	Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophrenia Bulletin, 2018, 44, 1133-1150.	2.3	99

#	Article	IF	CITATIONS
19	The influence of affective temperaments and psychopathological traits on the definition of bipolar disorder subtypes: A study on Bipolar I Italian National sample. Journal of Affective Disorders, 2012, 136, e41-e49.	2.0	98
20	Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis?. World Psychiatry, 2011, 10, 45-51.	4.8	97
21	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. Journal of Affective Disorders, 2016, 195, 105-118.	2.0	92
22	Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. Current Drug Targets, 2015, 16, 1094-1106.	1.0	89
23	Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Current Neuropharmacology, 2012, 10, 97-123.	1.4	85
24	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. American Journal of Psychiatry, 2020, 177, 76-92.	4.0	83
25	Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. Brain, Behavior, and Immunity, 2021, 97, 193-203.	2.0	80
26	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry, 2021, 20, 244-275.	4.8	76
27	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatric Disease and Treatment, 2016, 12, 719.	1.0	74
28	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. Current Neuropharmacology, 2018, 16, 583-606.	1.4	72
29	Al²1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy, 2014, 10, 1827-1843.	4.3	70
30	Depression and pain: primary data and meta-analysis among 237Â952 people across 47 low- and middle-income countries. Psychological Medicine, 2017, 47, 2906-2917.	2.7	70
31	Mediterranean Diet and its Benefits on Health and Mental Health: A Literature Review. Clinical Practice and Epidemiology in Mental Health, 2020, 16, 156-164.	0.6	70
32	A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. Journal of Affective Disorders, 2016, 196, 32-46.	2.0	69
33	The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. International Journal of Molecular Sciences, 2013, 14, 12458-12483.	1.8	66
34	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. International Journal of Molecular Sciences, 2015, 16, 1111-1130.	1.8	66
35	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction, 2016, 111, 1914-1922.	1.7	65
36	Incidence, prevalence and clinical correlates of antidepressantâ€emergent mania in bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2018, 20, 195-227.	1.1	60

#	Article	IF	CITATIONS
37	Aβ1â€42â€mediated downâ€regulation of Uch‣1 is dependent on NFâ€ÎºB activation and impaired BACE1 l degradation. Aging Cell, 2012, 11, 834-844.	ysosomal	57
38	Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. International Journal of Molecular Sciences, 2017, 18, 135.	1.8	57
39	Amyloid-β42 Activates the Expression of BACE1 Through the JNK Pathway. Journal of Alzheimer's Disease, 2011, 27, 871-883.	1.2	55
40	Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatric Disease and Treatment, 2013, 9, 243.	1.0	53
41	The relationship between the dietary inflammatory index (DII®) and incident depressive symptoms: A longitudinal cohort study. Journal of Affective Disorders, 2018, 235, 39-44.	2.0	50
42	The FDA "Black Box―Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry, 2019, 10, 294.	1.3	50
43	Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. Journal of Affective Disorders, 2013, 145, 300-307.	2.0	49
44	Lifetime co-morbidity with different subtypes of eating disorders in 148 females with bipolar disorders. Journal of Affective Disorders, 2010, 121, 147-151.	2.0	48
45	Suicide in Healthcare Workers: Determinants, Challenges, and the Impact of COVID-19. Frontiers in Psychiatry, 2021, 12, 792925.	1.3	47
46	Affective temperaments are associated with specific clusters of symptoms and psychopathology: A cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. Journal of Affective Disorders, 2013, 151, 540-550.	2.0	46
47	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. Archives of Suicide Research, 2017, 21, 100-112.	1.2	46
48	NGF serum levels variations in major depressed patients receiving duloxetine. Psychoneuroendocrinology, 2013, 38, 1824-1828.	1.3	45
49	Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. International Journal of Molecular Sciences, 2016, 17, 241.	1.8	43
50	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world,―everyday clinical practice. CNS Spectrums, 2017, 22, 342-347.	0.7	43
51	The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. Journal of Affective Disorders, 2020, 276, 970-983.	2.0	43
52	Different measures of impulsivity in patients with anxiety disorders: A case control study. Psychiatry Research, 2012, 197, 231-236.	1.7	42
53	The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications. Pharmacological Research, 2019, 139, 494-502.	3.1	42
54	Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants. Journal of Affective Disorders, 2015, 173, 211-215.	2.0	41

#	Article	IF	CITATIONS
55	Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking―in response towards subjective intolerance to pain. Journal of Affective Disorders, 2013, 151, 596-604.	2.0	39
56	Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Annals of General Psychiatry, 2011, 10, 5.	1.2	38
57	A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder. Journal of Affective Disorders, 2015, 178, 88-97.	2.0	38
58	Emotional Dysregulation in Adolescents: Implications for the Development of Severe Psychiatric Disorders, Substance Abuse, and Suicidal Ideation and Behaviors. Brain Sciences, 2020, 10, 591.	1.1	38
59	Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatric Disease and Treatment, 2011, 7, 51.	1.0	36
60	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study. Comprehensive Psychiatry, 2015, 58, 82-87.	1.5	36
61	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naÃ⁻ve patients with post-traumatic stress disorder: an exploratory study in the everyday â€real world' clinical practice. International Journal of Psychiatry in Clinical Practice, 2020, 24, 83-87.	1.2	36
62	Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion on Investigational Drugs, 2016, 25, 719-728.	1.9	35
63	Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management. Neuropsychiatric Disease and Treatment, 2010, 6, 209.	1.0	33
64	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. Journal of Affective Disorders, 2021, 295, 740-751.	2.0	33
65	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. Current Pharmaceutical Design, 2019, 25, 381-387.	0.9	33
66	Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. Clinical Practice and Epidemiology in Mental Health, 2010, 6, 20-24.	0.6	32
67	VEGF plasma level variations in duloxetine-treated patients with major depression. Journal of Affective Disorders, 2013, 151, 590-595.	2.0	32
68	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Revista Brasileira De Psiquiatria, 2021, 43, 189-202.	0.9	32
69	The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review. CNS and Neurological Disorders - Drug Targets, 2013, 12, 252-264.	0.8	32
70	Impulsivity in anxiety disorder patients: Is it related to comorbid cyclothymia?. Journal of Affective Disorders, 2011, 133, 600-606.	2.0	31
71	The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. International Review of Psychiatry, 2017, 29, 425-435.	1.4	31
72	Gut Microbiota and Bipolar Disorder: An Overview on a Novel Biomarker for Diagnosis and Treatment. International Journal of Molecular Sciences, 2021, 22, 3723.	1.8	31

#	Article	IF	CITATIONS
73	Obsessive-compulsive disorder and related disorders: a comprehensive survey. Annals of General Psychiatry, 2009, 8, 13.	1.2	30
74	The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?. Expert Opinion on Pharmacotherapy, 2012, 13, 2037-2051.	0.9	30
75	Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators of Inflammation, 2016, 2016, 1-8.	1.4	30
76	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. International Journal of Molecular Sciences, 2017, 18, 349.	1.8	30
77	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naÃ⁻ve patients with firstâ€episode major depression: An exploratory study in the "real world―everyday clinical practice. Microbial Biotechnology, 2020, 14, 336-342.	0.9	30
78	How common is bipolar disorder in general primary care attendees? A systematic review and meta-analysis investigating prevalence determined according to structured clinical assessments. Australian and New Zealand Journal of Psychiatry, 2016, 50, 631-639.	1.3	29
79	Alexithymia, Suicide Ideation and Homocysteine Levels in Drug NaÃ ⁻ ve Patients with Major Depression: A Study in the "Real World" Clinical Practice. Clinical Psychopharmacology and Neuroscience, 2019, 17, 318-322.	0.9	29
80	The impact of premenstrual dysphoric disorder among 92 bipolar patients. European Psychiatry, 2010, 25, 450-454.	0.1	28
81	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. Journal of Affective Disorders, 2021, 280, 409-431.	2.0	28
82	Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clinical Psychopharmacology and Neuroscience, 2021, 19, 174-178.	0.9	28
83	Sensation seeking in major depressive patients: Relationship to sub-threshold bipolarity and cyclothymic temperament. Journal of Affective Disorders, 2013, 148, 375-383.	2.0	27
84	Inflammatory markers and suicidal attempts in depressed patients: A review. International Journal of Immunopathology and Pharmacology, 2016, 29, 583-594.	1.0	27
85	Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy, 2019, 20, 1925-1933.	0.9	27
86	Electroretinographic assessment in major depressed patients receiving duloxetine: Might differences between responders and non-responders indicate a differential biological background?. Journal of Affective Disorders, 2011, 135, 154-159.	2.0	26
87	Unexplained Somatic Symptoms during Major Depression: Prevalence and Clinical Impact in a National Sample of Italian Psychiatric Outpatients. Psychopathology, 2011, 44, 116-124.	1.1	25
88	Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 289-301.	2.5	25
89	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. Current Pharmaceutical Design, 2016, 22, 5144-5162.	0.9	25
90	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. Current Topics in Medicinal Chemistry, 2020, 20, 554-584.	1.0	25

#	Article	IF	CITATIONS
91	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. Current Clinical Pharmacology, 2013, 8, 256-264.	0.2	25
92	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. CNS and Neurological Disorders - Drug Targets, 2017, 16, 65-92.	0.8	25
93	Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2014, 8, 30-37.	0.7	24
94	Is there cardiac risk in panic disorder? An updated systematic review. Journal of Affective Disorders, 2016, 194, 38-49.	2.0	24
95	The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 132, 289-303.	2.9	24
96	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International, 2017, 2017, 1-17.	0.9	23
97	Amyloid-β42 Plasma Levels are Elevated in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 18, 267-271.	1.2	22
98	βâ€Amyloid 1â€42 induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry, 2012, 122, 1023-1031.	2.1	22
99	Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data. International Journal of Immunopathology and Pharmacology, 2013, 26, 299-304.	1.0	22
100	The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention. Psychiatry Research, 2018, 269, 658-672.	1.7	21
101	Prevalence and clinical features associated to bipolar disorder–migraine comorbidity: a systematic review. Comprehensive Psychiatry, 2015, 56, 1-16.	1.5	20
102	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. Epidemiology and Psychiatric Sciences, 2020, 29, e14.	1.8	20
103	Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 771-775.	1.2	19
104	BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurological Sciences, 2015, 36, 729-734.	0.9	19
105	The Relationship between Dietary Vitamin K and Depressive Symptoms in Late Adulthood: A Cross-Sectional Analysis from a Large Cohort Study. Nutrients, 2019, 11, 787.	1.7	19
106	Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice. Brain Sciences, 2020, 10, 912.	1.1	19
107	Medicine and psychiatry in Western culture: Ancient Greek myths and modern prejudices. Annals of General Psychiatry, 2009, 8, 21.	1.2	18
108	Discriminative Hypomania Checklist-32 Factors in Unipolar and Bipolar Major Depressive Patients. Psychopathology, 2012, 45, 390-398.	1.1	18

#	Article	IF	CITATIONS
109	The Interface between Neuroscience and Neuro-Psychoanalysis: Focus on Brain Connectivity. Frontiers in Human Neuroscience, 2016, 10, 20.	1.0	18
110	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 2016, 16, 483-495.	1.4	18
111	Catatonia: A Narrative Review. Central Nervous System Agents in Medicinal Chemistry, 2011, 11, 73-79.	0.5	17
112	Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opinion on Pharmacotherapy, 2011, 12, 2817-2831.	0.9	17
113	A case of deep venous thrombosis following protracted catatonic immobility recovered with electroconvulsive therapy: the relevance for an early intervention. General Hospital Psychiatry, 2012, 34, 209.e5-209.e7.	1.2	17
114	Prevalence and correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents without dementia: systematic review and meta-analysis. British Journal of Psychiatry, 2020, 216, 6-15.	1.7	17
115	Cancer diagnosis and suicide outcomes: Umbrella review and methodological considerations. Journal of Affective Disorders, 2021, 295, 1201-1214.	2.0	17
116	Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series. Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25, 343-345.	0.9	16
117	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders, 2018, 234, 131-138.	2.0	16
118	Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World Journal of Biological Psychiatry, 2010, 11, 991-996.	1.3	14
119	Agomelatine in the treatment of panic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 286-287.	2.5	14
120	Obsessive-Compulsive Aspects and Pathological Gambling in an Italian Sample. BioMed Research International, 2014, 2014, 1-10.	0.9	14
121	Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial. European Neuropsychopharmacology, 2014, 24, 1269-1278.	0.3	14
122	Factor structure and reliability of the Arabic adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Comprehensive Psychiatry, 2015, 59, 141-150.	1.5	14
123	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Journal of Affective Disorders, 2015, 178, 112-120.	2.0	14
124	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world―chart review study. Revista Brasileira De Psiquiatria, 2020, 42, 317-321.	0.9	14
125	Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?. Neuropsychiatric Disease and Treatment, 2014, 10, 907.	1.0	13
126	Pharmacological management of depression in patients with multiple sclerosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1533-1540.	0.9	13

#	Article	IF	CITATIONS
127	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine. Current Pharmaceutical Design, 2021, 27, 3293-3304.	0.9	13
128	Does the "Silver Bullet―Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. Clinical Practice and Epidemiology in Mental Health, 2016, 12, 142-157.	0.6	12
129	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective. Expert Opinion on Drug Discovery, 2018, 13, 221-228.	2.5	12
130	The â€~dead man walking' disorder: an update on Cotard's syndrome. International Review of Psychiatry, 2020, 32, 500-509.	1.4	12
131	"Novel Psychopharmacology for Depressive Disordersâ€: Advances in Experimental Medicine and Biology, 2021, 1305, 449-461.	0.8	12
132	Trazodone Add-on in COVID-19-related Selective Serotonin Reuptake Inhibitor-resistant Post-traumatic Stress Disorder in Healthcare Workers: Two Case Reports. Clinical Psychopharmacology and Neuroscience, 2021, 19, 780-785.	0.9	12
133	Editorial: "No Words for Feelings, Yet!―Exploring Alexithymia, Disorder of Affect Regulation, and the "Mind-Body―Connection. Frontiers in Psychiatry, 2020, 11, 593462.	1.3	11
134	Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report. Clinical Psychopharmacology and Neuroscience, 2018, 16, 505-507.	0.9	11
135	Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Annals of General Psychiatry, 2008, 7, 26.	1.2	10
136	Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. Neuropsychiatric Disease and Treatment, 2011, 7, 217.	1.0	10
137	Experimental drugs for bipolar psychosis. Expert Opinion on Investigational Drugs, 2016, 25, 1371-1375.	1.9	10
138	Psychological perspective of medication adherence in transplantation. World Journal of Transplantation, 2016, 6, 736.	0.6	10
139	Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease. International Journal of Molecular Sciences, 2021, 22, 13032.	1.8	10
140	Agomelatine reversal of escitalopramâ€induced apathy: A case report. Psychiatry and Clinical Neurosciences, 2013, 67, 190-191.	1.0	9
141	Emerging Mania Following Escitalopram Withdrawal in a Patient with Unipolar Depression Managed with its Reintroduction. Journal of Psychiatric Practice, 2014, 20, 228-231.	0.3	9
142	In Memory of Hagop Akiskal. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 48-51.	0.6	9
143	Previous Functional Social and Behavioral Rhythms Affect Resilience to Covid-19-Related Stress among Old Adults. Journal of Public Health Research, 2022, 11, jphr.2022.2768.	0.5	9
144	Epileptic Seizures but not Pseudoseizures are Associated with Decreased Density of the Serotonin Transporter in Blood Platelet Membranes. Neurochemical Research, 2008, 33, 2263-2268.	1.6	8

#	Article	IF	CITATIONS
145	Clozapine-Related Pericarditis During Titration Phase in a Patient With Resistant Schizophrenia and Concomitant Valproate Treatment. Journal of Clinical Psychopharmacology, 2014, 34, 649-651.	0.7	8
146	Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. Journal of Affective Disorders, 2018, 228, 118-124.	2.0	8
147	Psychometric properties of the Patient Health Questionnaire nine-item version (PHQ-9) for use among hospitalized non-psychiatric medical patients. General Hospital Psychiatry, 2019, 61, 69-75.	1.2	8
148	Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine. Neuropsychiatric Disease and Treatment, 2010, 6, 719.	1.0	7
149	Somatopsychic Correlates and Quality of Life of the Dialyzed Patient: A Cross-Sectional Study. Transplantation Proceedings, 2014, 46, 2199-2202.	0.3	7
150	Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases. Frontiers in Psychiatry, 2020, 11, 438.	1.3	7
151	Cotard's Syndrome after breast surgery successfully treated with aripiprazole augmentation of escitalopram: a case report. Rivista Di Psichiatria, 2015, 50, 95-8.	0.6	7
152	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine, 2022, 11, 3935.	1.0	7
153	A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin. General Hospital Psychiatry, 2012, 34, 321.e1-321.e4.	1.2	6
154	The shocking attitude toward electroconvulsive therapy in Italy. CNS Spectrums, 2020, , 1-3.	0.7	6
155	Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report. Annals of General Psychiatry, 2010, 9, 39.	1.2	5
156	An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects. Annals of General Psychiatry, 2011, 10, 23.	1.2	5
157	Successful Use of Agomelatine in the Treatment of Major Depression in a Woman Taking Tamoxifen. Clinical Neuropharmacology, 2014, 37, 31-33.	0.2	5
158	Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression. Journal of Psychiatric Research, 2021, 136, 522-528.	1.5	5
159	Prominent autistic traits and subthreshold bipolar/mixed features of depression in severe anorexia nervosa. Revista Brasileira De Psiquiatria, 2020, 42, 153-161.	0.9	5
160	Melatonin and melatoninâ€agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and metaâ€analysis. Human Psychopharmacology, 2022, 37, e2821.	0.7	5
161	The relationship between drive to thinness, conscientiousness and bulimic traits during adolescence: a comparison between younger and older cases in 608 healthy volunteers. Annals of General Psychiatry, 2013, 12, 34.	1.2	4
162	Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report. Neuropsychiatric Disease and Treatment, 2014, 10, 1039.	1.0	4

#	Article	IF	CITATIONS
163	Overcoming the Use of Mechanical Restraints in Psychiatry: A New Challenge in the Everyday Clinical Practice at the Time of COVID-19. Journal of Clinical Medicine, 2020, 9, 3774.	1.0	4
164	Earthquakes, economic crisis and, now, COVID-19: the cry of yell of Central Italy Psychiatry Research, 2020, 291, 113181.	1.7	4
165	Comparison of familial and non-familial suicidal behaviors among people with major depressive disorder: Testing the discriminative predicting role of high-yield clinical variables. Journal of Psychiatric Research, 2018, 102, 118-122.	1.5	3
166	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia. , 2019, , 349-367.		3
167	Preclinical Considerations about Affective Disorders and Pain: A Broadly Intertwined, yet Often Under-Explored, Relationship Having Major Clinical Implications. Medicina (Lithuania), 2020, 56, 504.	0.8	3
168	A bibliometric analysis of scientific production on atypical antipsychotic drugs from Italy. Rivista Di Psichiatria, 2017, 52, 236-246.	0.6	3
169	Atypical Antipsychotics in Major Depressive Disorder. , 2018, , 257-268.		2
170	Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations. Expert Opinion on Pharmacotherapy, 2019, 20, 123-126.	0.9	2
171	Case of aripiprazole longâ€actingâ€related akathisia successfully managed with carvedilol: A case report. Psychiatry and Clinical Neurosciences, 2021, 75, 114-115.	1.0	2
172	Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. Clinical Practice and Epidemiology in Mental Health, 2010, 1, 20-24.	0.6	2
173	Cotard's Syndrome: Clinical Case Presentation and Literature Review. International Neuropsychiatric Disease Journal, 2014, 2, 348-355.	0.1	2
174	The effect of paliperidone palmitate long-acting injectable (PP-LAI) on "non-core" symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the "real world" everyday clinical practice. Rivista Di Psichiatria, 2021, 56, 143-148.	0.6	2
175	A Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials. Case Reports in Medicine, 2010, 2010, 1-5.	0.3	1
176	Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders. , 2016, , 219-228.		1
177	Melatonin, Sleep, Circadian Rhythm, and Mood Disorders. , 2016, , 117-127.		1
178	Reply to Dr. Sharma' "Understanding antidepressant tachyphylaxis― Pharmacological Research, 2019, 141, 620.	3.1	1
179	Reply to Dr. Gentili' "Analysis of tolerance to antidepressant drugs in FDA Adverse Event Reporting System― Pharmacological Research, 2019, 141, 618.	3.1	1
180	Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion on Pharmacotherapy, 2022, 23, 255-262.	0.9	1

11

#	Article	IF	CITATIONS
181	The Role of Agomelatine in the Treatment of Anxiety Disorders. , 2014, , 297-305.		1
182	Novel experimental and early investigational drugs for the treatment of bipolar disorder. Expert Opinion on Investigational Drugs, 2021, , 1-7.	1.9	1
183	Neurological, Psychiatric, and Psychological Implications of the COVID-19 Pandemic: Protocol for a Large-Scale Umbrella Review of Observational Studies. International Journal of Environmental Research and Public Health, 2022, 19, 1681.	1.2	1
184	Comments on: â€~ã€~Socio-economic factors and suicide rates in European Union countries― Legal Medicine, 2012, 14, 278.	0.6	0
185	Is there a biosignature for lithium response in bipolar disorder? Evidence and implications. , 2021, , 365-372.		0
186	There are no "side―effects, just "core―effects of antipsychotic pharmacotherapy. Acta Psychiatrica Scandinavica, 2021, 143, 99-100.	2.2	0
187	Takotsubo Syndrome and Electroconvulsive Therapy: Time for Rigorous Assessment. Clinical Practice and Epidemiology in Mental Health, 2019, 15, 99-100.	0.6	0
188	Medicine and psychiatry in Western culture: among Ancient Greek myths and modern prejudices. Medicina Nei Secoli, 2009, 21, 1105-22.	0.1	0